Robin Gasiorowski - Concepedia

Author

Robin Gasiorowski

Concord Repatriation General Hospital ORCID

Also Known As

R. Gasiorowski, Robin E Gasiorowski, Robin E. Gasiorowski, Robin Edward Gasiorowski, Robin Gasiorowski

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Concord Repatriation General Hospital The University of Sydney Peter MacCallum Cancer Centre AbbVie (United States)Erasmus MC Cancer Institute

About

Robin Gasiorowski is an author at Concord Repatriation General Hospital specializing in medicine, immunotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	364
2	Immunology	6	6	341
3	Health Sciences	4	4	84
4	Cell Biology	1	1	18
5	Cellular Therapies	1	1	34

Robin Gasiorowski

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières, Journal of Clinical Oncology	2022	484
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, The Lancet Oncology Interim AnalysisLymphoid NeoplasiaMedicineImmunologyPathology	2021	245
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Blood	2020	158
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières, Leukemia	2024	87
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the <scp>COVID</scp>‐19 pandemic Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman, Internal Medicine Journal	2020	42
Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia Robin Gasiorowski, Miriam K. Forbes, Gabriel Silver, JAMA Network Open	2022	37
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Journal of Clinical Oncology Cell TherapyPd-1 BlockadeImmunologyPathologyPharmacotherapy	2020	34
Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Blood	2018	32
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance Joel Wight, Mimi Yue, Colm Keane, British Journal of Haematology	2019	32
A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission Jennifer L. Hsu, Christian Bryant, Michael S. Papadimitrious, OncoImmunology	2018	31

Page 1